Recurrent abnormalities can be used for risk group stratification in pediatric AMKL: A retrospective intergroup study

Jasmijn D.E. De Rooij, Riccardo Masetti, Marry M. Van Den Heuvel-Eibrink, Jean Michel Cayuela, Jan Trka, Dirk Reinhardt, Mareike Rasche, Edwin Sonneveld, Todd A. Alonzo, Maarten Fornerod, Martin Zimmermann, Martina Pigazzi, Rob Pieters, Soheil Meshinchi, C. Michel Zwaan, Franco Locatelli

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

80 Citaten (Scopus)

Samenvatting

Genetic abnormalities and early treatment response are the main prognostic factors in acute myeloid leukemia (AML). Acute megakaryoblastic leukemia (AMKL) is a rare subtype of AML. Deep sequencing has identified CBFA2T3/GLIS2 and NUP98/KDM5A as recurrent aberrations, occurring in similar frequencies as RBM15/MKL1 and KMT2A-rearrangements. We studied whether these cytogenetic aberrations can be used for risk group stratification. To assess frequencies and outcome parameters of recurrent cytogenetic aberrations in AMKL, samples and clinical data of patients treated by the Associazione Italiana Ematologia Oncologia Pediatrica, Berlin-Frankfurt-Munster Study Group, Children's Oncology Group, Dutch Childhood Oncology Group, and the Saint Louis Hôpital were collected, enabling us to screen 153 newly diagnosed pediatric AMKL cases for the aforementioned aberrations and to study their clinical characteristics and outcome. CBFA2T3/GLIS2 was identified in 16% of the cases; RBM15/MKL1, in 12%; NUP98/KDM5A and KMT2A rearrangements, in 9% each; and monosomy 7, in 6%. These aberrations were mutually exclusive. RBM15/MKL1-rearranged patients were significantly younger. No significant differences in sex and white blood cell count were found. NUP98/KDM5A, CBFA2T3/GLIS2, KMT2A-rearranged lesions and monosomy 7 (NCK-7) independently predicted a poor outcome, compared with RBM15/MKL1-rearranged patients and those with AMKL not carrying these molecular lesions. NCK-7-patients (n = 61) showed a 4-year probability of overall survival of 35 ± 6% vs 70 ± 5% in the RBM15/MKL1-other groups (n = 92, P < .0001) and 4-year probability of event-free survival of 33 ± 6% vs 62 ± 5% (P = .0013), the 4-year cumulative incidence of relapse being 42 ± 7% and 19 ± 4% (P = .003), respectively. We conclude that these genetic aberrations may be used for risk group stratification of pediatric AMKL and for treatment tailoring.

Originele taal-2Engels
Pagina's (van-tot)3424-3430
Aantal pagina's7
TijdschriftBlood
Volume127
Nummer van het tijdschrift26
DOI's
StatusGepubliceerd - 30 jun. 2016

Vingerafdruk

Duik in de onderzoeksthema's van 'Recurrent abnormalities can be used for risk group stratification in pediatric AMKL: A retrospective intergroup study'. Samen vormen ze een unieke vingerafdruk.

Citeer dit